Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch

Opus Genetics, Inc. (IRD) announced an update on their ongoing clinical study.

The Phase 3 study “Randomized, Double-masked, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants With Presbyopia” aims to test whether a once-daily eye drop can safely improve near vision in adults with age-related focus loss. This is important because it targets a very common condition with a simple, drop-based approach instead of surgery or reading glasses.

The trial tests 0.75% phentolamine ophthalmic solution, also known as Nyxol, against a placebo eye drop. The goal is to see if Nyxol can improve distance-corrected near vision while keeping side effects low enough for broad, long-term use.

The study is interventional and randomized, meaning participants are assigned by chance to Nyxol or placebo. It uses a parallel group design with triple masking, so patients, doctors, and outcome reviewers do not know who gets the active drop, and the main goal is to treat presbyopia rather than just observe it.

The trial was first submitted in August 2024, marking the formal launch of this late-stage program. It is now listed as completed, with the record most recently updated on March 10, 2026, signaling that top-line data may be near and regulatory or partnership decisions could follow.

For investors, a successful outcome could support Ocuphire Pharma, Inc.’s path to filing in the growing presbyopia treatment market, where non-invasive options compete with other drop developers and device makers. Positive data may lift sentiment and valuation, while weak results could shift capital toward rival eye-care names and broader ophthalmology plays.

The clinical study has been completed and recently updated, with more details available on the ClinicalTrials portal.

To learn more about IRD’s potential, visit the Opus Genetics, Inc. drug pipeline page.